ESSA Current Deferred Revenue vs Retained Earnings Analysis
| EPIX Stock | USD 6.20 0.04 0.64% |
ESSA Pharma financial indicator trend analysis is much more than just examining ESSA Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ESSA Pharma is a good investment. Please check the relationship between ESSA Pharma Current Deferred Revenue and its Retained Earnings accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.
Current Deferred Revenue vs Retained Earnings
Current Deferred Revenue vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ESSA Pharma Current Deferred Revenue account and Retained Earnings. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between ESSA Pharma's Current Deferred Revenue and Retained Earnings is -0.52. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of ESSA Pharma, assuming nothing else is changed. The correlation between historical values of ESSA Pharma's Current Deferred Revenue and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of ESSA Pharma are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Current Deferred Revenue i.e., ESSA Pharma's Current Deferred Revenue and Retained Earnings go up and down completely randomly.
Correlation Coefficient | -0.52 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from ESSA Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.Enterprise Value is likely to rise to about 97 M in 2024, whereas Selling General Administrative is likely to drop slightly above 7.6 M in 2024.
ESSA Pharma fundamental ratios Correlations
Click cells to compare fundamentals
ESSA Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ESSA Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
| Other Current Liab | 676.0 | 2.4M | 1.2M | 1.4M | 1.6M | 1.0M | |
| Total Current Liabilities | 1.2M | 3.9M | 2.3M | 3.5M | 4.0M | 3.3M | |
| Total Stockholder Equity | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 175.8M | |
| Other Liab | 19.6K | 16.5K | 127.4K | 20.4K | 18.3K | 17.4K | |
| Net Tangible Assets | 49.0M | 79.2M | 194.0M | 167.1M | 192.2M | 201.8M | |
| Retained Earnings | (81.0M) | (117.8M) | (152.9M) | (179.5M) | (161.5M) | (153.4M) | |
| Accounts Payable | 1.1M | 1.4M | 954.6K | 2.0M | 2.3M | 1.6M | |
| Cash | 56.3M | 137.8M | 57.1M | 33.7M | 38.8M | 37.2M | |
| Other Assets | (55.2K) | 198.2M | (446.0K) | 115.4M | 132.7M | 139.3M | |
| Net Receivables | 309.5K | 489.0K | 6.2K | 135.1K | 121.6K | 115.5K | |
| Inventory | 420.5K | (360.8K) | (309.5K) | 110.6M | 127.2M | 133.6M | |
| Other Current Assets | 24.3M | 2.2M | 1.8M | 585.4K | 673.2K | 639.6K | |
| Other Stockholder Equity | 31.2M | 36.4M | 44.0M | 49.0M | 56.4M | 59.2M | |
| Total Liab | 1.3M | 4.2M | 2.4M | 3.5M | 3.1M | 3.6M | |
| Total Current Assets | 80.6M | 197.6M | 169.5M | 148.8M | 171.1M | 179.7M | |
| Short Term Debt | 59.1K | 120.7K | 133.8K | 80.3K | 92.4K | 87.8K | |
| Common Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 335.9M | |
| Net Debt | (56.3M) | (137.5M) | (56.9M) | (33.6M) | (30.3M) | (31.8M) | |
| Non Current Assets Total | 55.2K | 567.7K | 446.0K | 325.3K | 292.7K | 301.5K | |
| Cash And Short Term Investments | 56.3M | 194.9M | 57.1M | 148.1M | 170.3M | 178.8M | |
| Common Stock Shares Outstanding | 22.4M | 38.5M | 44.0M | 44.1M | 50.7M | 53.2M | |
| Liabilities And Stockholders Equity | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
| Non Currrent Assets Other | (200.7K) | 277.6K | 259.5K | 257.2K | 295.8K | 201.5K | |
| Short Long Term Debt Total | 59.1K | 331.0K | 209.8K | 80.3K | 72.3K | 68.7K | |
| Net Invested Capital | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 103.4M | |
| Net Working Capital | 79.1M | 193.7M | 166.7M | 145.3M | 167.1M | 101.6M | |
| Capital Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 198.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ESSA Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ESSA Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Essa Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Essa Pharma Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for ESSA Stock analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.14) | Return On Equity (0.19) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.